

---

## Form 603

Corporations Law  
Section 671B

### Notice of initial substantial holder

---

To Company Name/Scheme QRxPharma Limited

ACN/ARSN \_\_\_\_\_

#### 1. Details of substantial holder (1)

Name JPMorgan Chase & Co. and its affiliates

ACN (if applicable) N/A

The holder became a substantial holder on 6<sup>th</sup> June 2007

#### 2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Persons' votes (5)	Voting power (6)
Ordinary	3,770,035	3,770,035	5.03%

#### 3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
JF Capital Partners Limited	Investment Management	2,250,000
J.P. Morgan Securities Australia Limited	Proprietary Positions	1,520,035

#### 4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
N/A			

#### 5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
		Cash	Non-cash	
See Appendix				

## 6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN (if applicable)	Nature of association
N/A	

## 7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
JPMorgan Chase & Co. and its affiliates	1111 Polaris Parkway, Columbus, Ohio 43240

## Signature

print name Lam Chee Kin capacity Executive Director, JPMorgan Chase Bank, N.A.  
sign here \_\_\_\_\_ date 8<sup>th</sup> June 2007

## DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
- (2) See the definition of “associate” in section 9 of the Corporations Law.
- (3) See the definition of “relevant interest” in sections 608 and 671B(7) of the Corporations Law.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
- (6) The person’s votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (7) Include details of:
  - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write “unknown”.
- (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

<b>For the period between 07 Feb 2007 to 06 Jun 2007</b>						
<b>Transaction date</b>	<b>Entity</b>	<b>Instruments</b>	<b>Type of transaction</b>	<b>Ccy</b>	<b>Price</b>	<b>Quantity</b>
27-Apr-2007	JFCP	QRxPharma Limited	Purchase	AUD	2.00	2,250,000
25-May-2007	JPMSAL	QRxPharma Limited	Purchase	AUD	2.06	150,000
28-May-2007	JPMSAL	QRxPharma Limited	Purchase	AUD	2.00	895,000
29-May-2007	JPMSAL	QRxPharma Limited	Purchase	AUD	1.90	8,464
30-May-2007	JPMSAL	QRxPharma Limited	Purchase	AUD	1.94	58,464
31-May-2007	JPMSAL	QRxPharma Limited	Purchase	AUD	1.90	37,500
01-Jun-2007	JPMSAL	QRxPharma Limited	Purchase	AUD	1.90	1,725,134
04-Jun-2007	JPMSAL	QRxPharma Limited	Purchase	AUD	1.85	1,464
06-Jun-2007	JPMSAL	QRxPharma Limited	Purchase	AUD	1.83	193,022
From 07-Feb-2007 to 06-Jun-2007	JPMSAL	QRxPharma Limited	Sell			(1,549,013)
"JFCP" = JF Capital Partners Limited						
"JPMSAL"=J.P.Morgan Securities Australia Limited						